BioClinica EDC deal should help settle investor Nicusa

E-clinical solutions provider BioClinica, not skipping a beat since a recent investor tantrum, has signed a three-year deal for enterprise-wide EDC technology and data management services with a top 10 drugmaker. The multimillion-dollar agreement centers on BioClinica Express and involves one division of the big pharma.

The division plans to use the BioClinica services for some 200 studies annually, according to an announcement. The partners will use a common CDISC data model that they have developed.

BioClinica says its client is migrating to paperless studies and will use the services to that end. This agreement follows BioClinica's February deal with Cephalon, also for enterprise-level EDC services.

Investor Nicusa Capital in late September called for executive resignations at BioClinica based on financial results and a "less synergistic integration" of the company's e-clinical and imaging businesses than management expected. BioClinica responded to the 5.6-percent shareholder that the company's board "supports management and its strategic plan."

- here's the BioClinica release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.